Company intelligence / Profile preview

Paragate Medical

Ownership: Private
Development stage: Phase 1

Overview

Paragate Medical’s IPUD has entered first-in-human trials as of early/mid 2024. The device aims to provide continuous, home-based management of fluid overload for chronic heart and kidney failure patients, especially those resistant to diuretics. Early results and feedback highlight its potential for reducing hospitalizations and improving quality of life by enabling remote monitoring and tailored therapy. A next-generation miniaturized system ("Gen2") will follow initial studies.

Therapeutic areas: CardiovascularNephrology
Modalities: DeviceNon-pharmacological therapy
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Paragate Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paragate Medical.

Explore the full profile